Published Online: Thursday, June 1, 2006

Merck's Gardasil, a vaccine that blocks viruses that cause most cervical cancers, has been given the green light by an FDA advisory committee. The panel voted 13 to 0, stating that the vaccine was safe and effective and should be approved.The FDA, which usually follows the panel's recommendation, is expected to make a decision this month.

The vaccine is indicated for the treatment of sexually transmitted diseases, particularly 4 strains of human papillomavirus that can cause cervical cancer and genital warts. A Merck official said that the vaccine could be recommended for women aged 9 to 26, but it would work best for individuals who have not yet had sex. The expected cost of the vaccine is $300 to $500 (for 3 injections given over 6 months).

Latest Articles
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Latest Issues